Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCK | P27707 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12995154 | 1.00 | DCK (0.31) | DCKMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL12995146 | 0.93 | ALDH1A1 (0.35) | DCKMEN1KMT2AALDH1A1HTT | |
| SCHEMBL12995147 | 0.93 | ALDH1A1 (0.35) | DCKMEN1KMT2AALDH1A1HTT | |
| SCHEMBL14039219 | 0.88 | KMT2A (0.35) | DCKMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL12995176 | 0.87 | TOP2A (0.30) | — | |
| SCHEMBL12995198 | 0.87 | — | — | |
| SCHEMBL12995199 | 0.87 | — | — | |
| SCHEMBL12995168 | 0.87 | ALB (0.37) | DCKMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL12995169 | 0.87 | ALB (0.37) | DCKMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL13881206 | 0.85 | LMNA (0.36) | DCKKMT2AHTTPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318934-B2 | Process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes | AVEXA LIMITED (AU) | 2012-11-27 | — | — | US | disclosed |
| US-20100305321-A1 | PROCESS FOR CHIRAL RESOLUTION OF 2-SUBSTITUTED 4-SUBSTITUTED 1,3-OXATHIOLANES | AVEXA LIMITED (AU) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305321-A1 | PROCESS FOR CHIRAL RESOLUTION OF 2-SUBSTITUTED 4-SUBSTITUTED 1,3-OXATHIOLANES | DHPS, ICMT, ORC3 | DCK 2444/4885MEN1 4210/4885KMT2A 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.